الفهرس 
COVEROnly 14 pages are availabe for public view
 |  | from | 268 |  |  |
| | | from | 268 | | |
Abstract
Hepatitis C has infected nearly 170 million people worldwide; Egypt has the highest prevalence for HCV.
There are various extra hepatic manifestations of HCV infection, hematological and non hematological, such as pulmonary fibrosis, cutaneous vasculitis, glomerulonephritis, Mooren’s ulcer, porphyria cutanea tarda and lichen planus, and hematological manifestations such as lymphoproliferative disorders, thrombocytopenia and anemmia.
The recommended therapy for chronic hepatitis C is a combination of formulations of interferon alfa and ribavirin
In this study we aimed to compare haematological disorders with HCV infection with and without antiviral treatment.
So we divided our patients into two groups, group1 who received the therapy and group2 who did not receive it.
The patients were collected from Ain shams University hospital. Full history, clinical examination was taken and they are subjected to hematological work up to detect any abnormality.
We found that HCV patients have low hemoglobin and platelet count.
We find also that the patients who didn’t receive the therapy have lower granulocytic and lymphocytes counts than patients received therapy and WBCs, ESR are also increased in patients who did not receive therapy. Liver enzymes and billirubin are normalized in patients received the therapy.
In the groupI, patients with sustained virologic response have higher WBC, HGB platelet than non responder patients and also had normal liver enzymes and coagulation profile. In contrast to non responder patients who had abnormal liver enzyme and coagulation profile.
We found statistically significant negative correlation in the 1st group (received the combined therapy) between viral load, platelet and MCHC. Also there was statistically significant positive correlation between viral load, monocyte, granulocytes and ESR.
Also we found statistically significant positive correlation between ALT and hemoglobin and statistically significant negative correlation between ALT and haematocrit, there was statistically significant positive correlation between billirubin, lymphocytes and monocytes and statistically significant negative correlation between billirubin and red blood cells.
We concluded that patients who received specific therapy suffered of benign hematological disorders as as, iron deficiency anemia, vitamin B12 deficiency, bone marrow aplasia and dysplasia while patients did not receive the specific therapy suffered more malignant disorders as, acute and chronic leukemia, B non Hodgkin lymphoma, waldenstrom macroglobulinemia.
Patients with HCV have high risk in developing auto immune phenomenon, but if it is lymphogenic or not or the therapy of HCV have a role in prevention or treat it there is a controversy about this.
So, we recommend that HCV patients should receive the therapy and patients with HCV who received the therapy or not should be followed up by complete hematological workup to detect any abnormalities.